Kura Oncology to Present at Wedbush PacGrow Healthcare Virtual Conference
August 04 2020 - 06:30AM
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage
biopharmaceutical company committed to realizing the promise of
precision medicines for the treatment of cancer, today announced
its participation at the 2020 Wedbush PacGrow Healthcare Virtual
Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive
Officer, is scheduled to present an overview of the company on
Tuesday, August 11, 2020 at 2:20 p.m. ET / 11:20 a.m. PT. The
virtual conference will be held from August 11-12, 2020.
A live audio webcast of the presentation will be available in
the Investors section of Kura’s website at www.kuraoncology.com,
with an archived replay available for 30 days following the
event.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company
committed to realizing the promise of precision medicines for the
treatment of cancer. The Company’s pipeline consists of two wholly
owned, small molecule drug candidates that target cancer signaling
pathways where there is a strong scientific and clinical rationale
to improve outcomes by identifying those patients most likely to
benefit from treatment. Kura’s most advanced drug candidate is
tipifarnib, a potent, selective and orally bioavailable farnesyl
transferase inhibitor currently in a registration-directed trial
(AIM-HN) in patients with recurrent or metastatic HRAS mutant head
and neck squamous cell carcinoma. The Company’s pipeline is also
highlighted by KO-539, a potent and selective inhibitor of the
menin-KMT2A(MLL) protein-protein interaction currently in a Phase
1/2A clinical trial (KOMET-001) in patients with
relapsed/refractory acute myeloid leukemia. For additional
information about Kura, please visit the Company’s website at
www.kuraoncology.com.
Contacts
Company:Pete De SpainVice President, Investor Relations
&Corporate Communications(858)
500-8803pete@kuraoncology.com
Investors:Robert H. UhlManaging DirectorWestwicke ICR(858)
356-5932robert.uhl@westwicke.com
Media:Jason SparkManaging DirectorCanale Communications(619)
849-6005jason@canalecomm.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Mar 2023 to Mar 2024